A new prognostic tool for CLL: CLL-IPI
Integrating midostaurin into FLT3 positive AML treatment
How should MRD be used for MM in routine clinical practice?
Why are new molecules typically combined with standard chemotherapy?
How to use social media in clinical trials - reaching out to patients